The FTC’s Second Request extends its review of the proposed MiMedx-Sanara MedTech merger, while a senior Justice Department official says antitrust prosecutors remain ready to litigate.
The Federal Trade Commission has demanded more information from MiMedx Group and Sanara MedTech about their proposed merger, valued at approximately $350 million. The request extends the federal review period and leaves the transaction under scrutiny.
Both companies disclosed on October 16 that they received an FTC Second Request the previous day, according to company filings cited by Business Insider. The agency seeks additional information and documents about the deal. Under the Hart-Scott-Rodino process, the waiting period continues until 30 days after the companies substantially comply, unless the FTC ends it sooner or the parties agree to an extension.
The review clock is therefore tied to the companies’ compliance, not simply to the date the agency issued its request. The disclosures do not say when the companies expect to complete their responses, so they do not establish when the waiting period will end. Nor do they describe a proposed resolution or say that the companies have agreed to change the transaction.
A Second Request is not a finding that a merger would violate antitrust law. It allows regulators to obtain more material before deciding whether to let a transaction proceed, seek changes, or challenge it. The request can extend the process and require additional work from the companies, but its issuance alone does not reveal what the FTC has concluded.
The public disclosures do not detail the agency’s concerns, the information it seeks, or a timetable for completing its review. They also do not establish whether the FTC sees a risk to competition. Treating the request as proof of an antitrust violation would overstate what is known; dismissing it as routine paperwork would understate the scrutiny the companies face.
The central question in merger review is whether a combination could weaken competition—not simply whether a business will become larger. For customers and smaller rivals, the practical concern is whether a deal could reduce meaningful alternatives or make it harder for competitors to win business. The available disclosures do not answer that question here.
The filings put the transaction’s value at approximately $350 million, but the public account offers no detailed description of its expected effects on customers, suppliers, or competitors. It does not identify the products or markets the FTC is examining, or explain whether the inquiry concerns overlapping operations or other competitive issues. Without those details, a definitive assessment of the deal’s market impact would be premature.
Separately, a senior Justice Department official said the Antitrust Division was expanding its litigation program and remained prepared to take cases to court, MLex reported October 17. The statement signals a willingness to litigate, but identifies no particular case or target and does not establish a change in approach to any specific investigation. It describes the division’s posture, not an announced enforcement action.
The FTC and DOJ share responsibility for federal antitrust enforcement. Their willingness to challenge mergers or business conduct matters when supported by evidence and a credible case in court. Vigorous scrutiny can protect competition; enforcement that reaches beyond the evidence can burden lawful transactions and undermine predictability. The public interest calls for rigorous review, clear explanations, and decisions that can withstand legal scrutiny.
For now, the MiMedx-Sanara matter is a review, not a verdict. The FTC has requested more information, and the companies’ compliance will determine when the waiting period resumes its countdown. The disclosures establish neither that the merger threatens consumers nor that it poses no competitive risk. What the agency concludes—and whether it explains any concerns—will determine whether the review leads to a challenge or clearance.
Greg Sanders serves as the Senior Correspondent for Corporate Power and Antitrust at Just Right News, where he brings a principled, conservative perspective to the complex intersection of big business, government regulation, and the American consumer. With a career dedicated to investigative depth and economic clarity, Greg has become a leading voice in examining how the consolidation of industry power impacts the foundational values of the free market and individual liberty.
Raised in Denver, Colorado, Greg’s reporting is deeply informed by the Western spirit of independence and a healthy skepticism of centralized authority. Growing up in the shadows of the Rockies, he witnessed firsthand the importance of local entrepreneurship and the vital role that small-medium enterprises play in sustaining vibrant communities. This upbringing instilled in him a belief that the American Dream is best preserved when the playing field remains level and when competition—rather than backroom deals between corporate lobbyists and federal regulators—dictates success. For Greg, the rugged individualism of his home state serves as a constant reminder that the economy should serve the people, not the other way around.
Now based in Chicago, Illinois, Greg operates from the heart of the nation’s industrial and financial crossroads. His location in the Midwest provides him with a unique vantage point to observe the real-world consequences of corporate overreach. From the boardrooms of the Loop to the manufacturing hubs that define the region, he tracks the movement of capital and the shifting tides of market influence. Chicago’s history as a center of trade and labor offers a rich backdrop for his work, allowing him to bridge the gap between high-level economic theory and the lived experiences of hardworking Americans who feel the squeeze of monopolistic practices.
At Just Right News, Greg’s beat focuses on the “new monopolies” and the rise of “woke” corporate culture. He argues that when corporations become too large, they often abandon their fiduciary duties to shareholders in favor of social engineering and political posturing. His reporting seeks to hold these “Titans” accountable, ensuring that the power of the purse is not used to silence dissent or bypass the democratic process. He is a firm advocate for the idea that true conservatism requires a vigilant defense of competition, preventing any single entity—public or private—from exerting undue control over the lives of citizens.
This mission is most clearly seen in his acclaimed feature series, “The Titans and the Toll.” In this ongoing project, Greg explores the human cost of market consolidation, from the erosion of consumer choice to the decline of local economies. Through rigorous analysis and boots-on-the-ground reporting, he documents how the concentration of power in sectors like tech, agriculture, and finance creates a “toll” paid by the average family.
Greg Sanders remains committed to the idea that a transparent, competitive market is the greatest engine for prosperity ever devised. Through his work at Just Right News, he continues to provide the essential oversight necessary to protect that engine from the encroaching influence of corporate giants and the bureaucratic structures that enable them.